|
 Home
|
|
|
Back
|
13 May 2008
|
Anti-CTSP-1 antibodies predict prostate cancer recurrence
|
MedWire News: Antibodies against the cancer-testis antigen CTSP-1 could lead to improved prognosis and treatment of prostate cancer, study findings published in the International Journal of Cancer suggest.
CTSP-1 is present in many prostate tumors and induces a humoral response in prostate cancer patients, Anamaria Camargo (Ludwig Institute for Cancer Research, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil) and colleagues explain.
To investigate further, the team determined the relationship between antibodies against CTSP-1 and the risk for biochemical recurrence after radical prostatectomy in 147 men with localized prostate cancer.
Overall, 25% of the patients carried antibodies against CTSP-1, and a significant correlation was detected between CTSP-1 expression and a humoral response in the men.
Analysis found no correlation between anti-CTSP-1 antibodies and pathologic characteristics, such as T and N staging, tumor size, and Gleason score.
However, men with antibodies against CTSP-1 had a trend toward better biochemical-free survival than men without the antibodies (75% vs 57%). Moreover, this difference in biochemical-free survival between men with and without anti-CTSP-1 antibodies was statistically significant for the subpopulation of men with a high Gleason score of 7-8 (36% vs 80%).
On multivariate analysis, the presence of anti-CTSP-1 antibodies was the third most significant indicator of a better prognosis, with a hazard ratio of 0.41, after Gleason score and preoperative prostate-specific antigen concentration.
"CTSP-1 should be considered a promising candidate for prostate cancer immunotherapy, since it is frequently expressed in prostate tumors and capable of eliciting humoral immune response in prostate cancer patients," Camargo et al say.
"Our results also suggest that humoral response against CTSP-1 could be used as a prognostic marker, especially among patients with a high Gleason score," they add.
Int J Cancer 2008; 122: 2385-2390
http://www3.interscience.wiley.com/journal/117892781/abstract
|
|
© 2006 CMG
|
|
Search
Information for
This is an AstraZeneca International website for healthcare professionals. The site is not intended for the following audiences who should use the links below:
Casodex news feed
Quick links
Features
|
 |
| |
|
|
